When prostate cancer reaches the fourth stage, metastasis and spread throughout the body, then we can no longer go about curing the patient. In this situation, doctors are fighting for as long as possible to prolong the life of patients. The new drug Zytiga Developed by British scientists at the Institute of Cancer Research, could give patients additional four months of life.
As shown in clinical studies, patients with prostate cancer the final stages of receiving the drug Zytiga (abiraterone acetate) in combination with steroids, on average, could survive after 15 months of treatment. And patients with standard steroid drugs could count only 11 months.
Besides that, Zytiga facilitates pain symptoms twice more men than traditional medicines. This was reported in the journal New England Journal of Medicine. According to scientists, the new drug can be effectively used among 80% of patients with drug-resistant form of aggression prostate cancer Who were already receiving various kinds of anti-hormonal treatment and chemotherapy.
The main aim of the founders was to translate Zytiga last stage of prostate cancer into a chronic disease through a combination of old and new drugs. This should significantly extend the life expectancy of patients.
Industry News
Go back to the main page
No comments:
Post a Comment